3 New Strong Buy Ratings from Top-Rated Analysts: 05/14/2026
Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Neurocrine Biosciences (NBIX) — 2,425% EPS growth fuels 61% upside potential.
- Tapestry (TPR) — Coach owner crushes earnings with 246% ROE.
- Beone Medicines (ONC) — Oncology giant scores FDA priority review catalyst.
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
At Any Given Moment, Only 8% of Stocks Are Worth Owning
The other 92%? They'll waste your time, your money, or both. Louis Navellier has spent 47 years building a system that separates the 8% from everything else - and he's offering 3 FREE searches so you can see where your stocks fall. A? B? C? F? Find out in seconds. No credit card required.
See Which Grade Your Stocks Earn
1. Tapestry (NYSE: TPR)
The global luxury accessories powerhouse behind Coach, Kate Spade, and Stuart Weitzman is defying retail headwinds in spectacular fashion. After Q3 2026 earnings crushed expectations and prompted a raised full-year guidance, TPR is proving that consumer demand for its viral Tabby bags and premium products is here to stay — with Coach driving exceptional performance across the portfolio.
Zen Rating: Strong Buy (A) — see full analysis
Recent Price: $131.57 — get current quote
Max 1-year forecast: $200.00
Why we're watching:
- Analyst support: 11 analysts cover TPR with 7 Strong Buy ratings, 3 Buy ratings, and only 1 Hold, reflecting widespread confidence in the luxury brand portfolio's trajectory. See the ratings
- For example, JP Morgan's Matthew Boss (a top 10% rated analyst) maintained his Street-high $200 price target, which suggests over 50% upside potential in the coming year. Boss emphasized the company's innovative product offerings and strong customer loyalty as driving forces for future growth.
- UBS analyst Jay Sole (top 8%) recently upgraded TPR to Strong Buy with a $187 price target, citing the company's brand strength and global market reach positioning it well for continued expansion.
- Industry ranking context: TPR ranks #2 in the Luxury industry, which carries an excellent A rating, demonstrating strong positioning in a high-performing sector, and the company ranks in the top 7% of 1,000+ stocks tracked overall.
- Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr, putting TPR in a class of top-notch performers.
- Component Grades: Looking at the Component Grades that build that overall rating, the company earns top marks with A grades in Sentiment and Financials (top 10% and top 12% percentile rankings respectively), plus solid B grades in Growth and from our proprietary AI factor, which sifts through mountains of data to detect subtle patterns that could lead to outperformance. (See all 7 Zen Component Grades here)
2. BeOne Medicines (NASDAQ: ONC)
Formerly known as BeiGene, this global oncology powerhouse is on the offensive with FDA priority review just granted for TEVIMBRA in first-line HER2+ gastroesophageal adenocarcinoma — a major near-term catalyst. Following Q1 2026 results and a stacked pipeline of upcoming catalysts, ONC is positioned to expand its oncology leadership with significant revenue growth ahead.
Zen Rating: Strong Buy (A) — see full analysis
Recent Price: $316.00 — get current quote
Max 1-year forecast: $425.00
Why we're watching:
- Analyst support: 7 analysts cover ONC with 4 Strong Buy ratings, 2 Buy ratings, and only 1 Hold, demonstrating strong conviction in the oncology specialist's growth trajectory. See the ratings
- Guggenheim's Michael Schmidt (a top 2% rated analyst) maintained his Strong Buy rating with a $420 price target, while RBC Capital's Leonid Timashev (top 7%) set a $425 target representing 36% upside potential.
- The FDA's recent grant of priority review for TEVIMBRA in first-line HER2+ gastroesophageal adenocarcinoma represents a major near-term catalyst, with potential approval expected to significantly expand the company's commercial footprint.
- Industry ranking context: ONC is currently the #5 highest-rated stock in the Biotech industry.
- Zen Rating highlights: ONC is an A-rated stock, meaning it ranks in the top 5% of the 4600+ stocks we track based on a rigorous 115-factor review.
- Component Grades: The company's balanced profile with B grades in Value, Growth, Sentiment, Financials, and AI, demonstrates strong fundamentals across multiple dimensions. (See all 7 Zen Component Grades here)
3. Neurocrine Biosciences Inc (NASDAQ: NBIX)
This fast-growing pharmaceutical powerhouse — armed with blockbuster treatments for tardive dyskinesia and congenital adrenal hyperplasia — just delivered a stunning Q1 2026 earnings beat with 42% year-over-year revenue growth. Now, with the pending acquisition of Soleno Therapeutics on the table, NBIX is set for major portfolio expansion and extended growth runways that have Wall Street buzzing.
Zen Rating: Strong Buy (A) — see full analysis
Recent Price: $155.92 — get current quote
Max 1-year forecast: $246.00
Why we're watching:
- Analyst support: 19 analysts cover NBIX with 10 Strong Buy ratings, 6 Buy ratings, and only 3 Hold ratings, demonstrating strong conviction across the Street. See the ratings
- Piper Sandler's David Amsellem (a top 6% rated analyst) raised his price target to $207 following Q1 earnings, noting the stock's risk/reward profile is "highly attractive" and trades at just 9x the firm's 2027 pro forma EBITDA estimate in the context of a company that will soon have three assets with lengthy exclusivity runways.
- The company reported impressive Q1 2026 results with EPS of $1.97 beating estimates, revenue of $814.5M (up 42.25% year-over-year), and remarkable year-over-year EPS growth of 2,362.5%, driven by continued strong demand for INGREZZA and CRENESSITY.
- Industry ranking context: NBIX is currently the #2 highest-rated stock in the Pharmaceutical industry (out of 52), which carries a B rating, demonstrating exceptional positioning in a solid sector.
- Zen Rating highlights: As a Strong Buy-rated stock, NBIX is in a class of equities that have historically delivered 32.52% annual returns.
- Component Grades: The company's A-grade Value and Financials scores combined with B grades in Growth, Sentiment, and AI demonstrate exceptional operational execution and market positioning. (See all 7 Zen Component Grades here)
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.